Trials / Completed
CompletedNCT01672905
PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
Evaluation of PSA Antibody on E9802: Confirmation and Concordance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Eastern Cooperative Oncology Group · Network
- Sex
- Male
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in samples from patients treated for prostate cancer on trial ECOG-E9802.
Detailed description
OBJECTIVES: Primary * To evaluate changes in prostate-specific antigen (PSA) antibody levels over time among patients treated on ECOG-E9802. Secondary * To characterize the concordance of PSA antibody assessment between the ECOG Immunology Laboratory and the NCI Immunology Laboratory. OUTLINE: Previously tested samples are evaluated for changes in PSA antibody levels over time (from baseline to follow-up at 12 and 24 weeks) at the ECOG Immunology Laboratory and the NCI Immunology Laboratory. Results are compared between the laboratories.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2012-12-07
- Primary completion
- 2013-01-07
- Completion
- 2013-01-07
- First posted
- 2012-08-27
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01672905. Inclusion in this directory is not an endorsement.